Stay updated with breaking news from Human Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan 29, 2024--
The EMA has validated for review a Type II variation application for Pfizer and Astellas Pharma’s PADCEV combination regimen for urothelial cancer.
HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase] becomes the Only Facilitated Subcutaneous Immunoglobulin, Offering Patients an up to Once-Monthly Treatment...
(RTTNews) - Takeda (TAK) said that the European Commission approved Hyqvia as maintenance therapy in patients of all ages with chronic inflammator...
Takeda TSE4502NYSETAK today announced that the European Commission EC approved HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy CIDP after stabilization with intravenous immunoglobulin therapy IVIG.